Today Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB) Reported Decrease in Shorted Shares

September 17, 2017 - By Vivian Park

 Today Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB) Reported Decrease in Shorted Shares

The stock of Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB) registered a decrease of 12.08% in short interest. CATB’s total short interest was 712,500 shares in September as published by FINRA. Its down 12.08% from 810,400 shares, reported previously. With 190,400 shares average volume, it will take short sellers 4 days to cover their CATB’s short positions. The short interest to Catabasis Pharmaceuticals Incorporated’s float is 6.81%.

The stock increased 0.60% or $0.01 on September 15, reaching $1.69. About 943,837 shares traded or 137.46% up from the average. Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has declined 73.74% since September 17, 2016 and is downtrending. It has underperformed by 90.44% the S&P500.

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $37.99 million. The Firm is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted , a linker drug discovery platform. It currently has negative earnings. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) Ratings Coverage

Among 5 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Catabasis Pharmaceuticals had 10 analyst reports since August 17, 2015 according to SRatingsIntel. The stock of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) earned “Hold” rating by Cowen & Co on Thursday, August 10. The stock of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) earned “Buy” rating by Wedbush on Monday, August 14. The company was maintained on Monday, August 17 by Wedbush. The rating was initiated by H.C. Wainwright with “Buy” on Thursday, December 22. On Monday, August 14 the stock rating was maintained by Oppenheimer with “Buy”. The company was maintained on Monday, August 14 by H.C. Wainwright. As per Wednesday, June 8, the company rating was maintained by Wedbush. The rating was maintained by Citigroup with “Buy” on Tuesday, March 22. Citigroup maintained the shares of CATB in report on Thursday, June 9 with “Buy” rating.

More notable recent Catabasis Pharmaceuticals Inc (NASDAQ:CATB) news were published by: Seekingalpha.com which released: “Catabasis Pharmaceuticals’ (CATB) CEO Jill Milne on Q1 2017 Results – Earnings …” on May 12, 2017, also Businesswire.com with their article: “Phase 2 Trial of Edasalonexent in Duchenne Muscular Dystrophy in a Late …” published on September 14, 2017, Marketwatch.com published: “Catabasis Pharma surges 17% on positive early-stage clinical trial results for …” on January 19, 2017. More interesting news about Catabasis Pharmaceuticals Inc (NASDAQ:CATB) were released by: Businesswire.com and their article: “Catabasis Pharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference” published on August 09, 2017 as well as Finance.Yahoo.com‘s news article titled: “Catabasis Pharmaceuticals Announces Favorable Results for Functional …” with publication date: April 25, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.